Go to: content | top | bottom | search
You are hereUNIL > Center for Integrative Genomics > Research > Research groups > Prof. Desvergne

Béatrice Desvergne, Professor

Béatrice Desvergne was trained as a MD. She initially specialized in Anesthesiology and Resuscitation, practiced medicine for a few years, and decided to move for fundamental research. She then carried out a post-doctoral stay from 1988 to 1992 at the National Institutes of Health in Bethesda, first as visiting fellow and then visiting associate in the National Institute of Diabetes and Digestive and Kidney Diseases. In 1992, she was appointed as Assistant Professor at the Institute of Animal Biology of the UNIL. After being appointed as Associate Professor, she was promoted as full Professor in 2008. She joined the Center for Integrative Genomics in 2003.

Peroxisome proliferator-activated receptor, development, tissue repair, energy homeostasis, signal transduction

Research summary

Networking activity of PPARs during development and in adult metabolic homeostasis
As they mediate intracellular hormone action, nuclear receptors play a crucial multi-faceted role in coordinating growth during development, and homeostasis at adult stage. Among them, the peroxisome-proliferator activated receptors (PPARs) act as fatty acids sensors, responding to dietary as well as to endogenous challenges. Accordingly, they have an integrative role in controlling the expression of genes regulating the storage, mobilization, and/or utilization of lipids. Using various molecular, cellular, and animal approaches, our studies are aimed at understanding how PPARs are integrated in the main pathways that shape the organism during development on the one hand and maintain systemic homeostasis on the other hand.

We were among the first to generate PPAR mutant mice. Following a clinician-type of approach, our activities have been centered on revealing and understanding at the molecular levels the phenotypic expressions of PPAR mutations, taking them as leads to explore the physiopathological significance and novel therapeutic advances that PPARs carry.

Our studies during development show that both PPARβ and PPARγ are required for placenta development but each has specific activities: on the differentiation of trophoblast giant cells, via activation of the PI3K pathway and inhibition of Id2 for PPARβ, and on vascular development via controlling the expression of angiogenic factors for PPARγ. Further studies of the role of PPARβ and PPARγ in development were impeded by a partially and fully penetrant lethality of PPARβ-/- and PPARγ-/- embryos, respectively, at embryonic day 10.5. However, we have now generated fully viable mutant embryos and live pups, through an epiblastic selective PPAR deletion. It demonstrates that the cause of embryonic lethality in PPAR mutants is mainly due to the placental defects and gives us new tols for exploring the role of PPARγ in late development and in adult tissues.

In the adult animals, the gut is a very interesting organ, combining critical metabolic functions and a tightly regulated and highly active cell renewal capacity, from few adult stem cells to highly differentiated enterocytes, Paneth, Goblet, and enterodendocrine cells. In this tissue, we demonstrated that decrease of Indian Hedgehog via PPARβ ensures the final maturation of Paneth cell precursors whereas PPARγ is rather involved in controlling inflammation processes. We are now further exploring the importance of PPARs in response to challenges, either metabolic, infectious, or physical damages, with the purpose of bringing our mechanistic approaches in mouse models closer to human pathologies.

The role of PPARs as mediating the activity of some endocrine disruptors was an important focus of our recent activity. To understand how endocrine disruptors behave at the molecular levels in the living cells, we used a combination of Fluorescence Recovery After Photobleaching (FRAP), Fluorescence Correlation Spectroscopy (FCS) and Fluorescence Resonance Energy Transfer (FRET). We first demonstrated that PPARs readily heterodimerize with retinoid X receptor (RXR) and exhibit a ligand-induced reduction of mobility, probably due to enhanced interactions with cofactors and/or chromatin. We also demonstrated that coregulator recruitment (and not DNA binding) plays a crucial role in receptor mobility, suggesting that transcriptional complexes are formed prior to promoter binding. This allowed us to demonstrate that, in the living cells, the pollutant monoethylhexyl-
phthalate (MEHP) directly binds to the ligand binding domain of PPAR and drives the recruitement of a specific subset of cofactors. We further analyzed the consequences in vivo of such activities and showed that MEHP protects mice from diet-induced obesity via a PPARα-dependent activation of hepatic fatty acid catabolism. This is accompanied by, and possibly due to, the up-regulation of the anti-obesity factor FGF21 hepatic expression. However, both effects are reversed in PPARα-humanized mice, underlining the importance of PPARα species-specific activities and questioning the impact of phthalates in human metabolic homeostasis.

Representative publications

F. Varnat, B. Bordier-ten Heggeler, P. Grisel, N. Boucard, I. Corthésy-Theulaz, W. Wahli, and B. Desvergne. (2006) PPARbeta/delta regulates Paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroentrology 131:538-53

Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Trono D, Wahli W, Desvergne B. (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol. 26:3266-81.

B. Desvergne, L. Michalik, W. Wahli. (2006) Transcriptional control of metabolism. Physiological Review, 86:465-514.

Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, Desvergne B. (2005). Fluorescence imaging reveals the nuclear behavior of PPAR/RXR heterodimers in the absence and presence of ligand. J Biol Chem. 280:17880-90.

E. Letavernier, J. Perez, E. Joye, A. Bellocq, B. Fouqueray, J-P Haymann, D. Heudes, W. Wahli, B. Desvergne, and L. Baud. (2005). PPARbeta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol. 16:2395-402.

2015 |  2014 |  2013 |  2012 |  2011 |  2010 |  2009 |  2008 |  2007 |  2006 |  2005 |  2004 |  2003 |  2002 |  2001 |  2000 |  1999 |  1998 |  1997 |  1996 |  1995 |  1994 |  1992 |  1991 |  1990 |  1989 |  1988 |  1987 |  Thèses (doctorat) | 

Garnier V., Traboulsi W., Salomon A., Brouillet S., Fournier T., Winkler C., Desvergne B., Hoffmann P., Zhou Q.Y., Congiu C. et al., 2015. PPARγ controls pregnancy outcome through activation of EG-VEGF: new insights into the mechanism of placental development. American Journal of Physiology. Endocrinology and Metabolism 309(4) pp. E357-E369. [DOI] [Web of Science] [Pubmed]
Giordano Attianese G.M., Desvergne B., 2015. Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function. Nuclear Receptor Signaling 13 pp. e001. [DOI] [Pubmed]
Piemontese L., Fracchiolla G., Carrieri A., Parente M., Laghezza A., Carbonara G., Sblano S., Tauro M., Gilardi F., Tortorella P. et al., 2015. Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175. European Journal of Medicinal Chemistry 90 pp. 583-594. [DOI] [Web of Science] [Pubmed]
Toffoli B., Desvergne B., 2015. PPAR Gamma Receptor, Skin Lipids and Hair. pp. 277-288 in Pappas A. (eds.) Lipids and skin health. Springer, New York. [DOI]
Fu H., Desvergne B., Ferrari S., Bonnet N., 2014. Impaired musculoskeletal response to age and exercise in PPARβ(-/-) diabetic mice. Endocrinology 155(12) pp. 4686-4696. [DOI] [Web of Science] [Pubmed]
Gilardi F., Desvergne B., 2014. RXRs: collegial partners. pp. 75-102 in Asson-Batres M.A., Rochette-Egly C. (eds.) The biochemistry of retinoic acid receptors I: structure, activation, and function at the molecular level. Subcellular Biochemistry 70. Springer, Dordrecht. [DOI] [Web of Science] [Pubmed]
Gilardi F., Migliavacca E., Naldi A., Baruchet M., Canella D., Le Martelot G., Guex N., Desvergne B., CycliX Consortium, 2014. Genome-wide analysis of SREBP1 activity around the clock reveals its combined dependency on nutrient and circadian signals. PLoS Genetics 10(3) pp. e1004155. [Document] [DOI] [Web of Science] [Pubmed]
Berger H., Végran F., Chikh M., Gilardi F., Ladoire S., Bugaut H., Mignot G., Chalmin F., Bruchard M., Derangère V. et al., 2013. SOCS3 Transactivation by PPARγ Prevents IL-17-Driven Cancer Growth. Cancer Research 73(12) pp. 3578-3590. [DOI] [Web of Science] [Pubmed]
Scholtysek C., Katzenbeisser J., Fu H., Uderhardt S., Ipseiz N., Stoll C., Zaiss M.M., Stock M., Donhauser L., Böhm C. et al., 2013. PPARβ/δ governs Wnt signaling and bone turnover. Nature Medicine 19(5) pp. 608-613. [DOI] [Web of Science] [Pubmed]
Brunner J.M., Plattet P., Doucey M.A., Rosso L., Curie T., Montagner A., Wittek R., Vandelvelde M., Zurbriggen A., Hirling H. et al., 2012. Morbillivirus glycoprotein expression induces ER stress, alters Ca2+ homeostasis and results in the release of vasostatin. PLoS One 7(3) pp. e32803. [Document] [DOI] [Web of Science] [Pubmed]
Canella D., Bernasconi D., Gilardi F., LeMartelot G., Migliavacca E., Praz V., Cousin P., Delorenzi M., Hernandez N., CycliX Consortium, 2012. A multiplicity of factors contributes to selective RNA polymerase III occupancy of a subset of RNA polymerase III genes in mouse liver. Genome Research 22(4) pp. 666-680. [DOI] [Web of Science] [Pubmed]
Le Martelot G., Canella D., Symul L., Migliavacca E., Gilardi F., Liechti R., Martin O., Harshman K., Delorenzi M., Desvergne B. et al., 2012. Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and associated epigenetic changes during diurnal cycles. PLoS Biology 10(11) pp. e1001442. [Document] [DOI] [Web of Science] [Pubmed]
Nadra K., Médard J.J., Mul J.D., Han G.S., Grès S., Pende M., Metzger D., Chambon P., Cuppen E., Saulnier-Blache J.S. et al., 2012. Cell autonomous lipin 1 function is essential for development and maintenance of white and brown adipose tissue. Molecular and Cellular Biology 32(23) pp. 4794-4810. [DOI] [Web of Science] [Pubmed]
Nadra K., Médard J.J., Quignodon L., Verheijen M.H., Desvergne B., Chrast R., 2012. Epineurial adipocytes are dispensable for Schwann cell myelination. Journal of Neurochemistry 123(5) pp. 662-667. [DOI] [Web of Science] [Pubmed]
Casals-Casas C., Desvergne B., 2011. Endocrine disruptors: from endocrine to metabolic disruption. Annual Review of Physiology 73 pp. 135-162. [DOI] [Web of Science] [Pubmed]
Yamamoto H., Williams E.G., Mouchiroud L., Cantó C., Fan W., Downes M., Héligon C., Barish G.D., Desvergne B., Evans R.M. et al., 2011. NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell 147(4) pp. 827-839. [DOI] [Web of Science] [Pubmed]
Feige J.N., Gerber A., Casals-Casas C., Yang Q., Winkler C., Bedu E., Bueno M., Gelman L., Auwerx J., Gonzalez F.J. et al., 2010. The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environmental Health Perspectives 118(2) pp. 234-241. [Document] [DOI] [Web of Science] [Pubmed]
Georgiadi A., Lichtenstein L., Degenhardt T., Boekschoten M.V., van Bilsen M., Desvergne B., Müller M., Kersten S., 2010. Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circulation Research 106(11) pp. 1712-1721. [DOI] [Web of Science] [Pubmed]
Harrington L.S., Moreno L., Reed A., Wort S.J., Desvergne B., Garland C., Zhao L., Mitchell J.A., 2010. The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension. PLoS One 5(3) pp. e9526. [Document] [DOI] [Web of Science] [Pubmed]
Kapoor A., Shintani Y., Collino M., Osuchowski M.F., Busch D., Patel N.S., Sepodes B., Castiglia S., Fantozzi R., Bishop-Bailey D. et al., 2010. Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. American Journal of Respiratory and Critical Care Medicine 182(12) pp. 1506-1515. [DOI] [Web of Science] [Pubmed]
Morgan H., Beck T., Blake A., Gates H., Adams N., Debouzy G., Leblanc S., Lengger C., Maier H., Melvin D. et al., 2010. EuroPhenome: a repository for high-throughput mouse phenotyping data. Nucleic Acids Research 38(Database issue) pp. D577-D585. [DOI] [Web of Science] [Pubmed]
Nadra K., Quignodon L., Sardella C., Joye E., Mucciolo A., Chrast R., Desvergne B., 2010. PPARgamma in placental angiogenesis. Endocrinology 151(10) pp. 4969-4981. [DOI] [Web of Science] [Pubmed]
Peyrin-Biroulet L., Beisner J., Wang G., Nuding S., Oommen S.T., Kelly D., Parmentier-Decrucq E., Dessein R., Merour E., Chavatte P. et al., 2010. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proceedings of the National Academy of Sciences of the United States of America 107(19) pp. 8772-8777. [DOI] [Web of Science] [Pubmed]
Sanderson L.M., Boekschoten M.V., Desvergne B., Müller M., Kersten S., 2010. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver. Physiological Genomics 41(1) pp. 42-52. [DOI] [Web of Science] [Pubmed]
Ali F.Y., Hall M.G., Desvergne B., Warner T.D., Mitchell J.A., 2009. PPAR beta/delta Agonists Modulate Platelet Function via a Mechanism Involving PPAR Receptors and Specific Association/Repression of PKC alpha-Brief Report. Arteriosclerosis Thrombosis and Vascular Biology 29(11) pp. 1871-1873. [DOI] [Web of Science]
Desvergne B., Feige J.N., Casals-Casas C., 05-2009. PPAR-mediated activity of phthalates: A link to the obesity epidemic? Molecular and cellular endocrinology 304(1-2) pp. 43-48. [DOI] [Web of Science] [Pubmed]
Desvergne B., Héligon C., 2009. Steroid hormone pulsing drives cyclic gene expression. Nature Cell Biology 11(9) pp. 1051-1053. [DOI] [Web of Science] [Pubmed]
Sanderson L.M., Degenhardt T., Koppen A., Kalkhoven E., Desvergne B., Müller M., Kersten S., 2009. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Molecular and Cellular Biology 29(23) pp. 6257-6267. [DOI] [Web of Science] [Pubmed]
Casals-Casas C., Feige J.N., Desvergne B., 2008. Interference of pollutants with PPARs: endocrine disruption meets metabolism. International Journal of Obesity 32 Suppl 6 pp. S53-S61. [DOI] [Web of Science] [Pubmed]
Hall M.G., Quignodon L., Desvergne B., 2008. Peroxisome Proliferator-Activated Receptor beta/delta in the Brain: Facts and Hypothesis. PPAR Research 2008 p. 780452. [Document] [DOI] [Pubmed]
Rotman N., Haftek-Terreau Z., Luecke S., Feige J., Gelman L., Desvergne B., Wahli W., 2008. PPAR disruption: Cellular mechanisms and physiological consequences. CHIMIA 62(5) pp. 340-344. [DOI] [Web of Science]
Anghel S.I., Bedu E., Vivier C.D., Descombes P., Desvergne B., Wahli W., 2007. Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry 282(41) pp. 29946-29957. [DOI] [Web of Science] [Pubmed]
Bedu E., Desplanches D., Pequignot J., Bordier B., Desvergne B., 06-2007. Double gene deletion reveals the lack of cooperation between PPARalpha and PPARbeta in skeletal muscle. Biochemical and Biophysical Research Communications 357(4) pp. 877-881. [DOI] [Web of Science] [Pubmed]
Berry A., Balard P., Coste A., Olagnier D., Lagane C., Authier H., Benoit-Vical F., Lepert J.C., Séguéla J.P., Magnaval J.F. et al., 2007. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. European Journal of Immunology 37(6) pp. 1642-1652. [DOI] [Web of Science] [Pubmed]
Desvergne B., 2007. PPARs special issue: anchoring the present to explore the future. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids 1771(8) pp. 913-914. [DOI] [Web of Science] [Pubmed]
Desvergne B., 2007. Retinaldehyde: more than meets the eye. Nature Medicine 13(6) pp. 671-673. [DOI] [Web of Science] [Pubmed]
Desvergne B., 2007. RXR: from partnership to leadership in metabolic regulations. Vitamins and Hormones 75 pp. 1-32. [DOI] [Web of Science] [Pubmed]
Feige J.N., Gelman L., Rossi D., Zoete V., Métivier R., Tudor C., Anghel S.I., Grosdidier A., Lathion C., Engelborghs Y. et al., 2007. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. Journal of Biological Chemistry 282(26) pp. 19152-19166. [DOI] [Web of Science] [Pubmed]
Gelman L., Feige J.N., Desvergne B., 2007. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids 1771(8) pp. 1094-1107. [DOI] [Web of Science] [Pubmed]
Indra A.K., Castaneda E., Antal M.C., Jiang M., Messaddeq N., Meng X., Loehr C.V., Gariglio P., Kato S., Wahli W. et al., 2007. Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes. Journal of Investigative Dermatology 127(5) pp. 1250-1260. [DOI] [Web of Science] [Pubmed]
Mandard S., Stienstra R., Escher P., Tan N.S., Kim I., Gonzalez F.J., Wahli W., Desvergne B., Müller M., Kersten S., 2007. Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. Cellular and Molecular Life Sciences 64(9) pp. 1145-1157. [Document] [DOI] [Web of Science] [Pubmed]
Michalik L., Zoete V., Krey G., Grosdidier A., Gelman L., Chodanowski P., Feige J.N., Desvergne B., Wahli W., Michielin O., 2007. Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior. Journal of Biological Chemistry 282(13) pp. 9666-9677. [DOI] [Web of Science] [Pubmed]
Pialat J.B., Cho T.H., Beuf O., Joye E., Moucharrafie S., Moucharaffie S., Langlois J.B., Nemoz C., Janier M., Berthezene Y. et al., 2007. MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice. NMR in Biomedicine 20(3) pp. 335-342. [DOI] [Web of Science] [Pubmed]
Tudor C., Feige J.N., Pingali H., Lohray V.B., Wahli W., Desvergne B., Engelborghs Y., Gelman L., 2007. Association with coregulators is the major determinant governing peroxisome proliferator-activated receptor mobility in living cells. Journal of Biological Chemistry 282(7) pp. 4417-4426. [DOI] [Web of Science] [Pubmed]
Wang H., Xie H., Sun X., Tranguch S., Zhang H., Jia X., Wang D., Das S.K., Desvergne B., Wahli W. et al., 2007. Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success. Journal of Biological Chemistry 282(52) pp. 37770-37782. [DOI] [Web of Science] [Pubmed]
Ali F.Y., Egan K., FitzGerald G.A., Desvergne B., Wahli W., Bishop-Bailey D., Warner T.D., Mitchell J.A., 2006. Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. American Journal of Respiratory Cell and Molecular Biology 34(2) pp. 242-246. [DOI] [Web of Science] [Pubmed]
Desvergne B., Michalik L., Wahli W., 2006. Transcriptional regulation of metabolism. Physiological Reviews 86(2) pp. 465-514. [DOI] [Web of Science] [Pubmed]
Feige J.N., Gelman L., Michalik L., Desvergne B., Wahli W., 2006. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Progress in Lipid Research 45(2) pp. 120-159. [DOI] [Web of Science] [Pubmed]
Gelman L., Feige J.N., Tudor C., Engelborghs Y., Wahli W., Desvergne B., 2006. Integrating nuclear receptor mobility in models of gene regulation. Nuclear Receptor Signaling 4 pp. e010. [Document] [DOI] [Pubmed]
Knauf C., Rieusset J., Foretz M., Cani P.D., Uldry M., Hosokawa M., Martinez E., Bringart M., Waget A., Kersten S. et al., 2006. Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain. Endocrinology 147(9) pp. 4067-4078. [DOI] [Web of Science] [Pubmed]
Nadra K., Anghel S.I., Joye E., Tan N.S., Basu-Modak S., Trono D., Wahli W., Desvergne B., 2006. Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Molecular and Cellular Biology 26(8) pp. 3266-3281. [DOI] [Web of Science] [Pubmed]
Rotman N., Michalik L., Desvergne B., Wahli W., 2006. PPARs in fetal and early postnatal development. pp. 33-64 in Tanejah R. (eds.) Nuclear receptors in development. Advances in Developmental Biology 16. Elsevier, Amsterdam. [DOI]
Schuler M., Ali F., Chambon C., Duteil D., Bornert J.M., Tardivel A., Desvergne B., Wahli W., Chambon P., Metzger D., 2006. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metabolism 4(5) pp. 407-414. [DOI] [Web of Science] [Pubmed]
Varnat F., Heggeler B.B., Grisel P., Boucard N., Corthésy-Theulaz I., Wahli W., Desvergne B., 2006. PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology 131(2) pp. 538-553. [DOI] [Web of Science] [Pubmed]
Varnat F., Michalik L., Desvergne B., Wahli W., 2006. PPARs: lipid sensors that regulate cell differentiation processes. pp. 117-131 in Brigelius-Flohé R., Joost H.G. (eds.) Nutritional genomics : impact on health and disease. Wiley-VCH, Weinheim. [DOI]
Wang D., Wang H., Guo Y., Ning W., Katkuri S., Wahli W., Desvergne B., Dey S.K., DuBois R.N., 2006. Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proceedings of the National Academy of Sciences of the United States of America 103(50) pp. 19069-19074. [DOI] [Web of Science] [Pubmed]
Bedu E., Wahli W., Desvergne B., 2005. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. Expert Opinion On Therapeutic Targets 9(4) pp. 861-873. [DOI] [Web of Science] [Pubmed]
Debril M.B., Dubuquoy L., Feige J.N., Wahli W., Desvergne B., Auwerx J., Gelman L., 2005. Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity. Journal of Molecular Endocrinology 35(3) pp. 503-517. [DOI] [Web of Science] [Pubmed]
Di-Poï N., Desvergne B., Michalik L., Wahli W., 2005. Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins. Journal of Biological Chemistry 280(46) pp. 38700-38710. [DOI] [Web of Science] [Pubmed]
Di-Poï N., Ng C.Y., Tan N.S., Yang Z., Hemmings B.A., Desvergne B., Michalik L., Wahli W., 2005. Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development. Molecular and Cellular Biology 25(5) pp. 1696-1712. [DOI] [Web of Science] [Pubmed]
Eumorphia_Consortium, Wahli W., Delgado MB., Desvergne B., Michalik L., Bedu E., 2005. EMPReSS: standardised phenotype screens for functional annotation of the mouse genome. Nature Genetics 37(11) p. 1155. [DOI] [Web of Science] [Pubmed]
Feige J.N., Gelman L., Tudor C., Engelborghs Y., Wahli W., Desvergne B., 2005. Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand. Journal of Biological Chemistry 280(18) pp. 17880-17890. [DOI] [Web of Science] [Pubmed]
Feige J.N., Sage D., Wahli W., Desvergne B., Gelman L., 2005. PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs. Microscopy Research and Technique 68(1) pp. 51-58. [DOI] [Web of Science] [Pubmed]
Gelman L., Michalik L., Desvergne B., Wahli W., 2005. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Current Opinion in Cell Biology 17(2) pp. 216-222. [DOI] [Web of Science] [Pubmed]
Genolet R., Kersten S., Braissant O., Mandard S., Tan N.S., Bucher P., Desvergne B., Michalik L., Wahli W., 2005. Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha. Journal of Biological Chemistry 280(25) pp. 24143-24152. [DOI] [Web of Science] [Pubmed]
Gremlich S., Nolan C., Roduit R., Burcelin R., Peyot M.L., Delghingaro-Augusto V., Desvergne B., Michalik L., Prentki M., Wahli W., 2005. Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation. Endocrinology 146(1) pp. 375-382. [DOI] [Web of Science] [Pubmed]
Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.P., Heudes D., Wahli W., Desvergne B., Baud L., 2005. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. Journal of the American Society of Nephrology 16(8) pp. 2395-2402. [DOI] [Web of Science] [Pubmed]
Metzger D., Imai T., Jiang M., Takukawa R., Desvergne B., Wahli W., Chambon P., 2005. Functional role of RXRs and PPARgamma in mature adipocytes. Prostaglandins, Leukotrienes, and Essential Fatty Acids 73(1) pp. 51-58. [DOI] [Web of Science] [Pubmed]
Michalik L., Feige J.N., Gelman L., Pedrazzini T., Keller H., Desvergne B., Wahli W., 2005. Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing. Molecular Endocrinology 19(9) pp. 2335-2348. [DOI] [Web of Science] [Pubmed]
Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., Metzger D., Wahli W., Desvergne B., Naccari G.C. et al., 2005. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. Journal of Experimental Medicine 201(8) pp. 1205-1215. [Document] [DOI] [Web of Science] [Pubmed]
Tan N.S., Michalik L., Desvergne B., Wahli W., 2005. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. Journal of Steroid Biochemistry and Molecular Biology 93(2-5) pp. 99-105. [DOI] [Web of Science] [Pubmed]
Desvergne B., Michalik L., Wahli W., 2004. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Molecular Endocrinology 18(6) pp. 1321-1332. [DOI] [Web of Science] [Pubmed]
Di-Poï N., Michalik L., Desvergne B., Wahli W., 2004. Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis. Lipids 39(11) pp. 1093-1099. [DOI] [Web of Science] [Pubmed]
Ijpenberg A., Tan N.S., Gelman L., Kersten S., Seydoux J., Xu J., Metzger D., Canaple L., Chambon P., Wahli W. et al., 2004. In vivo activation of PPAR target genes by RXR homodimers. EMBO Journal 23(10) pp. 2083-2091. [DOI] [Web of Science] [Pubmed]
Imai T., Takakuwa R., Marchand S., Dentz E., Bornert J.M., Messaddeq N., Wendling O., Mark M., Desvergne B., Wahli W. et al., 2004. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proceedings of the National Academy of Sciences of the United States of America 101(13) pp. 4543-4547. [DOI] [Web of Science] [Pubmed]
Mao-Qiang M., Fowler A.J., Schmuth M., Lau P., Chang S., Brown B.E., Moser A.H., Michalik L., Desvergne B., Wahli W. et al., 2004. Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. Journal of Investigative Dermatology 123(2) pp. 305-312. [DOI] [Web of Science] [Pubmed]
Michalik L., Desvergne B., Wahli W., 2004. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nature Reviews. Cancer 4(1) pp. 61-70. [DOI] [Web of Science] [Pubmed]
Rieusset J., Seydoux J., Anghel S.I., Escher P., Michalik L., Soon Tan N., Metzger D., Chambon P., Wahli W., Desvergne B., 2004. Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action. Molecular Endocrinology 18(10) pp. 2363-2377. [DOI] [Web of Science] [Pubmed]
Tan N.S., Michalik L., Desvergne B., Wahli W., 2004. Peroxisome proliferator-activated receptor-beta as a target for wound healing drugs. Expert Opinion on Therapeutic Targets 8(1) pp. 39-48. [DOI] [Web of Science] [Pubmed]
Tan N.S., Michalik L., Di-Poï N., Desvergne B., Wahli W., 2004. Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing. Biochemical Society Transactions 32(Pt 1) pp. 97-102. [DOI] [Web of Science] [Pubmed]
Tan N.S., Michalik L., Di-Poï N., Ng C.Y., Mermod N., Roberts A.B., Desvergne B., Wahli W., 2004. Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression. EMBO Journal 23(21) pp. 4211-4221. [DOI] [Web of Science] [Pubmed]
Wang D., Wang H., Shi Q., Katkuri S., Walhi W., Desvergne B., Das S.K., Dey S.K., DuBois R.N., 2004. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6(3) pp. 285-295. [DOI] [Web of Science] [Pubmed]
Di-Poï N., Michalik L., Tan N.S., Desvergne B., Wahli W., 2003. The anti-apoptotic role of PPARbeta contributes to efficient skin wound healing. Journal of Steroid Biochemistry and Molecular Biology 85(2-5) pp. 257-265. [DOI] [Web of Science] [Pubmed]
Michalik L., Desvergne B., Wahli W., 2003. Peroxisome proliferator-activated receptors beta/delta: emerging roles for a previously neglected third family member. Current Opinion in Lipidology 14(2) pp. 129-135. [DOI] [Web of Science] [Pubmed]
Michalik L., Tan N. S., Wahli W., Desvergne B., 2003. PPARs: nuclear receptors involved in the control of inflammation. pp. 419-435 in Duttaroy A.K., Spener F. (eds.) Cellular proteins and their fatty acids in health and disease. Wiley VCH, Weinheim.
Tan N.S., Michalik L., Desvergne B., Wahli W., 2003. Peroxisome proliferator-activated receptor (PPAR)-beta as a target for wound healing drugs: what is possible? American Journal of Clinical Dermatology 4(8) pp. 523-530. [DOI] [Web of Science] [Pubmed]
Desvergne B., Michalik L., Wahli W., 2002. Sensors for metabolic control : a regulatory network of nuclear receptors. pp. 283-304 in Goffin V., Kelly P.A. (eds.) Hormone signaling. Endocrine updates 17. Kluwer Academic Publishers, Norwell.
Di-Poï N., Tan N.S., Michalik L., Wahli W., Desvergne B., 2002. Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Molecular Cell 10(4) pp. 721-733. [DOI] [Web of Science] [Pubmed]
Fauconnet S., Lascombe I., Chabannes E., Adessi G.L., Desvergne B., Wahli W., Bittard H., 2002. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. Journal of Biological Chemistry 277(26) pp. 23534-23543. [DOI] [Web of Science] [Pubmed]
Guissouma H., Dupré S.M., Becker N., Jeannin E., Seugnet I., Desvergne B., Demeneix B.A., 07-2002. Feedback on hypothalamic TRH transcription is dependent on thyroid hormone receptor N terminus. Molecular Endocrinology 16(7) pp. 1652-1666. [DOI] [Web of Science] [Pubmed]
Kersten S., Desvergne B., Wahli W., 2002. Peroxisome Proliferator Activated Receptor alpha coordinates intermediary metabolism during fasting. pp. 1-4 in Fruchart J.C., Gotto A.M., Paoletti R., Staels B., Catapano A.L. (eds.) PPARs : from basic science to clinical applications. Medical Science Symposia Series 18. Kluwer Academics Publishers, Boston.
Michalik L., Desvergne B., Dreyer C., Gavillet M., Laurini R.N., Wahli W., 01-2002. PPAR expression and function during vertebrate development. International Journal of Developmental Biology 46(1) pp. 105-114. [Web of Science] [Pubmed]
Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., Wahli W., 2002. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Molecular Endocrinology 16(11) pp. 2628-2644. [DOI] [Web of Science] [Pubmed]
Rodondi N., Darioli R., Ramelet A.A., Hohl D., Lenain V., Perdrix J., Wietlisbach V., Riesen W.F., Walther T., Medinger L. et al., 2002. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Annals of Internal Medicine 136(8) pp. 582-589. [Web of Science] [Pubmed]
Tan N.S., Shaw N.S., Vinckenbosch N., Liu P., Yasmin R., Desvergne B., Wahli W., Noy N., 2002. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Molecular and Cellular Biology 22(14) pp. 5114-5127. [DOI] [Web of Science] [Pubmed]
Canaple L., Nurdin N., Angelova N., Hunkeler D., Desvergne B., 2001. Development of a coculture model of encapsulated cells. Annals of the New York Academy of Sciences 944 pp. 350-361. [DOI] [Web of Science] [Pubmed]
Canaple L., Nurdin N., Angelova N., Saugy D., Hunkeler D., Desvergne B., 2001. Maintenance of primary murine hepatocyte functions in multicomponent polymer capsules-in vitro cryopreservation studies. Journal of Hepatology 34(1) pp. 11-18. [DOI] [Web of Science] [Pubmed]
Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P. et al., 2001. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. Journal of Experimental Medicine 193(7) pp. 827-838. [Document] [DOI] [Web of Science] [Pubmed]
Escher P., Braissant O., Basu-Modak S., Michalik L., Wahli W., Desvergne B., 10-2001. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142(10) pp. 4195-4202. [DOI] [Web of Science] [Pubmed]
Kersten S., Mandard S., Escher P., Gonzalez F.J., Tafuri S., Desvergne B., Wahli W., 2001. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB Journal 15(11) pp. 1971-1978. [DOI] [Web of Science] [Pubmed]
Michalik L., Desvergne B., Tan N.S., Basu-Modak S., Escher P., Rieusset J., Peters J.M., Kaya G., Gonzalez F.J., Zakany J. et al., 2001. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. Journal of Cell Biology 154(4) pp. 799-814. [Document] [DOI] [Web of Science] [Pubmed]
Rieusset J., Wahli W., Desvergne B., 2001. Les récepteurs nucléaires PPARs (Peroxisome Proliferator Activated Receptors) : Trois isotypes pour de multiples fonctions. Médecine Thérapeutique Endocinologie et Reproduction 3 pp. 4-12. [url editor site]
Tan N.S., Michalik L., Noy N., Yasmin R., Pacot C., Heim M., Flühmann B., Desvergne B., Wahli W., 12-2001. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes and Development 15(24) pp. 3263-3277. [DOI] [Web of Science] [Pubmed]
Kersten S., Desvergne B., Wahli W., 05-2000. Roles of PPARs in health and disease. Nature 405(6785) pp. 421-424. [DOI] [Web of Science] [Pubmed]
Kersten S., Mandard S., Tan N.S., Escher P., Metzger D., Chambon P., Gonzalez F.J., Desvergne B., Wahli W., 2000. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. Journal of Biological Chemistry 275(37) pp. 28488-28493. [DOI] [Web of Science] [Pubmed]
Michalik L., Desvergne B., Basu-Modak S., Tan N.S., Wahli W., 2000. Nuclear hormone receptors and mouse skin homeostasis: implication of PPARbeta. Hormone Research 54(5-6) pp. 263-268. [DOI] [Web of Science] [Pubmed]
Michalik L., Desvergne B., Wahli W., 2000. Les bases moléculaires de l'obésité : vers de nouvelles thérapeutiques ? Medecine Sciences 16(10) pp. 1030-1039. [Web of Science]
Nurdin N., Canaple L., Bartkowiak A., Desvergne B., Hunkeler D., 2000. Capsule permeability via polymer and protein ingress/egress. Journal of Applied Polymers Science 75(9) pp. 1165-1175. [DOI] [Web of Science]
Bartkowiak A., Canaple L., Ceausoglu I., Nurdin N., Renken A., Rindisbacher L., Wandrey C., Desvergne B., Hunkeler D., 06-1999. New multicomponent capsules for immunoisolation. Annals of the New York Academy of Sciences 875 pp. 135-145. [DOI] [Web of Science] [Pubmed]
Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P., Wahli W., 1999. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures. Journal of Biological Chemistry 274(50) pp. 35881-35888. [Document] [DOI] [Web of Science] [Pubmed]
Bernard P., Goudonnet H., Artur Y., Desvergne B., Wahli W., 09-1999. Activation of the mouse TATA-less and human TATA-containing UDP-glucuronosyltransferase 1A1 promoters by hepatocyte nuclear factor 1. Molecular Pharmacology 56(3) pp. 526-536. [Web of Science] [Pubmed]
Desvergne B., Wahli W., 10-1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20(5) pp. 649-688. [DOI] [Web of Science] [Pubmed]
Devchand P.R., Ijpenberg A., Devesvergne B., Wahli W., 1999. PPARs: nuclear receptors for fatty acids, eicosanoids, and xenobiotics. Advances in Experimental Medicine and Biology 469 pp. 231-236. [Web of Science] [Pubmed]
Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., Wahli W., 06-1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. Journal of Clinical Investigation 103(11) pp. 1489-1498. [DOI] [Web of Science] [Pubmed]
Wahli W., Devchand P.R., IJpenberg A., Desvergne B., 1999. Fatty acids, eicosanoids, and hypolipidemic agents regulate gene expression through direct binding to peroxisome proliferator-activated receptors. Advances in Experimental Medicine and Biology 447 pp. 199-209. [Web of Science] [Pubmed]
Wahli W., Kersten S., Devchand P., Desvergne B., 1999. PPARα : cross-talk with membrane receptors and control of energy homeostasis. pp. 159-167 in Imura H., Kasuga M, Nakao K. (eds.) Common disease : genetic and pathogenetic aspects of multifactorial diseases. Excerpta Medica. International Congress Series 1181. Elsevier, Amsterdam.
Desvergne B., IJpenberg A., Devchand P.R., Wahli W., 04-1998. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. Journal of Steroid Biochemistry and Molecular Biology 65(1-6) pp. 65-74. [DOI] [Web of Science] [Pubmed]
Jeannin E., Robyr D., Desvergne B., 09-1998. Transcriptional regulatory patterns of the myelin basic protein and malic enzyme genes by the thyroid hormone receptors alpha1 and beta1. Journal of Biological Chemistry 273(37) pp. 24239-24248. [DOI] [Web of Science] [Pubmed]
Juge-Aubry C., Pernin A., Favez T., Burger A.G., Wahli W., Meier C.A., Desvergne B., 10-1997. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region. Journal of Biological Chemistry 272(40) pp. 25252-25259. [DOI] [Web of Science] [Pubmed]
Masmoudi T., Hihi A.K., Vázquez M., Artur Y., Desvergne B., Wahli W., Goudonnet H., 1997. Transcriptional regulation by triiodothyronine of the UDP-glucuronosyltransferase family 1 gene complex in rat liver. Comparison with induction by 3-methylcholanthrene. Journal of Biological Chemistry 272(27) pp. 17171-17175. [DOI] [Web of Science] [Pubmed]
Desvergne B., 1996. Peroxisome proliferation and its role in carcinogenesis. ISSX Newsletter 16 p. 29.
Lemberger T., Desvergne B., Wahli W., 1996. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annual Review of Cell and Developmental Biology 12 pp. 335-363. [DOI] [Web of Science] [Pubmed]
Lemberger T., Saladin R., Vázquez M., Assimacopoulos F., Staels B., Desvergne B., Wahli W., Auwerx J., 01-1996. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. Journal of Biological Chemistry 271(3) pp. 1764-1769. [DOI] [Web of Science] [Pubmed]
Desvergne B., Wahli W., 1995. PPAR: a key nuclear factor in nutrient/gene interactions ? pp. 142-176 in Baeuerle P. A. (eds.) Inducible gene expression. Vol. 1, environmental stresses and nutrients. Progress in gene expression . Birkhäuser, Boston.
Wahli W., Braissant O., Desvergne B., 05-1995. Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more.... Chemistry and Biology 2(5) pp. 261-266. [DOI] [Web of Science] [Pubmed]
Desvergne B., 04-1994. How do thyroid hormone receptors bind to structurally diverse response elements? Molecular and Cellular Endocrinology 100(1-2) pp. 125-131. [DOI] [Web of Science] [Pubmed]
Lazar J., Desvergne B., Zimmerman E.C., Zimmer D.B., Magnuson M.A., Nikodem V.M., 08-1994. A role for intronic sequences on expression of thyroid hormone receptor alpha gene. Journal of Biological Chemistry 269(32) pp. 20352-20359. [Web of Science] [Pubmed]
Lemberger T., Staels B., Saladin R., Desvergne B., Auwerx J., Wahli W., 10-1994. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. Journal of Biological Chemistry 269(40) pp. 24527-24530. [Web of Science] [Pubmed]
Farsetti A., Desvergne B., Hallenbeck P., Robbins J., Nikodem V.M., 08-1992. Characterization of myelin basic protein thyroid hormone response element and its function in the context of native and heterologous promoter. Journal of Biological Chemistry 267(22) pp. 15784-15788. [Web of Science] [Pubmed]
Desvergne B., Petty K.J., Nikodem V.M., 01-1991. Functional characterization and receptor binding studies of the malic enzyme thyroid hormone response element. Journal of Biological Chemistry 266(2) pp. 1008-1013. [Web of Science] [Pubmed]
Farsetti A., Mitsuhashi T., Desvergne B., Robbins J., Nikodem V.M., 12-1991. Molecular basis of thyroid hormone regulation of myelin basic protein gene expression in rodent brain. Journal of Biological Chemistry 266(34) pp. 23226-23232. [Web of Science] [Pubmed]
Nikodem V.M., Petty K.J., Mitsuhashi T., Desvergne B., 1990. Structure and mechanism of action of thyroid hormone receptors. pp. 307-321 in Greer M. A. (eds.) The thyroid gland. Comprehensive Endocrinology . Raven Press, New York.
Petty K.J., Desvergne B., Mitsuhashi T., Nikodem V.M., 05-1990. Identification of a thyroid hormone response element in the malic enzyme gene. Journal of Biological Chemistry 265(13) pp. 7395-7400. [Web of Science] [Pubmed]
Desvergne B., Baffet G., Loyer P., Rissel M., Lescoat G., Guguen-Guillouzo C., Brissot P., 06-1989. Chronic iron overload inhibits protein secretion by adult rat hepatocytes maintained in long-term primary culture. European journal of cell biology 49(1) pp. 162-170. [Web of Science] [Pubmed]
Lescoat G., Desvergne B., Loreal O., Pasdeloup N., Deugnier Y., Bourel M., Brissot P., 1989. Modulation of albumin secretion by ornithine alpha-ketoglutarate in adult rat hepatocyte cultures and a human hepatoma cell line (HepG2). Annals of Nutrition and Metabolism 33(5) pp. 252-260. [DOI] [Web of Science] [Pubmed]
Lescoat G., Jouanolle H., Desvergne B., Pasdeloup N., Kneip B., Deugnier Y., Guillouzo A., Brissot P., 1989. Effects of iron overload on transferrin secretion by cultured fetal rat hepatocytes. Biology of the Cell 65(3) pp. 221-229. [DOI] [Web of Science] [Pubmed]
Etienne P.L., Baffet G., Desvergne B., Boisnard-Rissel M., Glaise D., Guguen-Guillouzo C., 1988. Transient expression of c-fos and constant expression of c-myc in freshly isolated and cultured normal adult rat hepatocytes. Oncogene Research 3(3) pp. 255-262. [Web of Science] [Pubmed]
Lescoat G., Loreal O., Desvergne B., Pasdeloup N., Deugnier Y., Brissot P., 12-1988. Effect of ornithine on transferrin secretion of rat and human hepatocyte cultures. Liver 8(6) pp. 360-365. [Web of Science] [Pubmed]
Brissot P., Farjanel J., Bourel D., Campion J.P., Guillouzo A., Rattner A., Deugnier Y., Desvergne B., Ferrand B., Simon M. et al., 06-1987. Chronic liver iron overload in the baboon by ferric nitrilotriacetate. Morphologic and functional changes with special reference to collagen synthesis enzymes. Digestive Diseases and Sciences 32(6) pp. 620-627. [DOI] [Web of Science] [Pubmed]
Jouanolle H., Lescoat G., Desvergne B., Deugnier Y., Brissot P., Bourel M., 10-1987. Surcharge hépatique en fer et synthèse protéique progrès apportés par les modèles expérimentaux. Annales de gastroentérologie et d'hépatologie 23(5) pp. 269-272. [Web of Science] [Pubmed]
Phd thesis
SCHIFFRIN M., 2016. Sex Dimorphism of Nonalcoholic Fatty Liver Disease. Université de Lausanne, Faculté de biologie et médecine, DESVERGNE B. (dir.).
Fu H., 2011. Nuclear receptor PPARS function in stem cell differentiation and bone physiology. 156 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.).
Hall M., 2011. PPAR beta a player in astrocyte metabolism and morphology. 138 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.).
Oommen S. T., 11-2011. Role of pparß in irradiation mediated intestinal damage. These, 192 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.). [Document]
Brunner J.-M., 2009. Canine distemper virus : persistence and pathology in the central nervous system. 172 p., Université de Lausanne, Faculté de biologie et médecine, Desvergnes B. (dir.).
Feige J., 2006. Integrating receptor interactions and dynamics and Interference with endocrine disruptors in the mechanisms of action of PPAR nuclear receptors. 187 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.).
Schumann A., 2006. Early antibiotic administration affects the gut barrier function and the immune response to oral antigen in suckling rats. 137 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.).
Nadra K., 2005. Roles of PPARβ and PPARγ in mouse placental development. 137 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.).
Boucard N., 2004. Roles of murine PPARβ in neuronal differentiation and cerebral ischemia. 145 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.).
Varnat F., 2004. PPARβ as a molecular link between Wnt and Hedgehog signaling pathways in intestinal development and repair. 111 p., Université de Lausanne, Faculté de biologie et médecine, Desvergne B. (dir.).


PixFRET, an ImageJ plug-in for FRET calculation which can accommodate variations in spectral bleed-throughs

Jérôme Feige1, Daniel Sage2, Walter Wahli1, Béatrice Desvergne1 and Laurent Gelman1

1 - Center for Integrative Genomics, NCCR frontiers in Genetics, University of Lausanne, Switzerland.
2 - Biomedical Imaging Group (BIG), Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.

Fluorescence Resonance Energy Transfer (FRET) is a technique used to investigate interactions between fluorescent partners that has gained great interest for cell biologists with the recent introduction of auto-fluorescent proteins which can be coupled to a protein of interest to produce a fluorescent chimera.

A plethora of methods exists to calculate FRET, depending on the protocol used (e.g. sensitized emission versus acceptor photobleaching) and the precision that is pursued (for a review, see "FRET or no FRET: a quantitative comparison", Biophysical J., 2003:84 p.3992-4010).

The ImageJ plug-in PixFRET allows to generate images of FRET, and hence to visualize FRETwithin a cell or a cell population, by computing pixel by pixel the images of a sample acquired in a three channel setting, according to the formula and the methodology described by Gordon et al (Quantitative fluorescence resonance energy transfer measurements using fluorescence microscopy, Biophysical J., 1998:74(5), p.2702-13) and Xia and Liu ("Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscopes", Biophysical J., 2001:81(4), p.2395-402).

 FRET Image Website_1.jpg

ExpNFRET reduces inter-cellular variability in pixel-by-pixel analyses.

Plug-in installation

  1. Download the PixFRET.zip file
  2.     Double click on the PixFRET.zip icon to extract the plug-in. This will create a folder with two new files. The ".jar" file is the plug-in and the ".pdf" file the user's guide.
  3.     Place the ".jar" file in the "Plugins" folder in ImageJ.
  4.     Start ImageJ again to display the new plug-in in the "Plugins" menu.

Note that ImageJ is a public-domain software package for image processing. It is free and it doesn't take more than a couple of minutes to install (http.//rsb.info.nih.gov/ij), it runs on any platforms: Unix, Linux, Windows, Mac OS9, Mac OSX.




Béatrice Desvergne


Tel: +41 21 692 4140


Administrative assistant

Carine Dovat
Tel: +41 21 692 4110

CH-1015 Lausanne  - Switzerland  -  Tel. +41 21 692 22 00  -  Fax +41 21 692 22 11
Swiss University